Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019

Ali Bukhari, Jonathan Siglin, Forat Lutfi, Ankit J. Kansagra, Jean Yared, Aaron P. Rapoport, Saurabh Dahiya

Research output: Contribution to journalArticlepeer-review

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.

Original languageEnglish (US)
Article number103007
JournalCritical Reviews in Oncology/Hematology
Volume152
DOIs
StatePublished - Aug 2020

Keywords

  • Chimeric antigen receptor T-cell therapy
  • Cytokine release syndrome
  • Leukemia
  • Lymphoma
  • Neurotoxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019'. Together they form a unique fingerprint.

Cite this